Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Targeting Cellulite as a Metabolic-Dermal Interface: Effects of Tirzepatide and a Multi-Pathway Topical Therapy (G21) in a 12-Month Observational Study.

PMID: 42147579 · 2026

JournalCureus
Year2026
PMID42147579

Abstract

Background Cellulite is a highly prevalent condition associated with alterations in adipose tissue architecture, microcirculation, and connective tissue integrity. Emerging evidence suggests that cellulite may represent a manifestation of both local structural changes and systemic metabolic dysfunction. This study aimed to evaluate the independent and combined effects of systemic metabolic therapy with tirzepatide and a multi-target topical formulation (G21) on cellulite severity and body compos

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.